Archaeosome Adjuvant Overcomes Tolerance to Tumor-Associated Melanoma Antigens Inducing Protective CD8+ T Cell Responses
Figure 2
Tumor protection following heterologous prime-boost vaccination. C57BL/6J mice were vaccinated subcutaneously with a single dose of Ms-OVA (20 μg OVA, 38 μg/mg lipid loading, 94.1 nm average archaeosome size), LM-OVA (104 CFU), or BCG-OVA (104 CFU) or with a prime-boost regimen as indicated. Mice were challenged with subcutaneous B16-OVA tumors 4 weeks post vaccination. Survival plots are based on euthanizing animals upon reaching a maximum tumor size of 300 mm2 (). Survival curves for vaccinated groups were significantly different from naïve group by log-rank test (**, ***).
